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In the present study, we demonstrated that D-aspartate acts as an in vitro and in vivo 
neuromodulatory molecule upon hippocampal NMDAR transmission. Accordingly, we showed 
that this D-amino acid, widely expressed during embryonic phase, was able to strongly influence 
hippocampus-related functions at adulthood. Thus, while up-regulated levels of D-aspartate 
increased LTP and spatial memory in four-month old adult mice, the prolonged deregulation of 
this molecule in thirteen-month old animals induced a substantial acceleration of age-dependent 
decay of synaptic plasticity and cognitive functions. Moreover, we highlighted a role for D-
aspartate in enhancing NMDAR-dependent synaptic plasticity through an inducible “turn-on/turn-
off-like mechanism”. Strikingly, we also showed that D-aspartate, when administered to aged 
mice, strongly rescued their physiological synaptic decay and attenuated their cognitive 
deterioration. In conclusion, our data suggest a tantalizing hypothesis for which this in-embryo-
occurring D-amino acid, might disclose plasticity windows in the aging brain. 
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 INTRODUCTION 
Cognitive processes are believed to depend on changes in synaptic efficacy in certain key brain 
regions, including the hippocampus1. Among different forms of synaptic plasticity, hippocampal N-
methyl D-aspartate receptors (NMDARs)-dependent Long-Term Potentiation (LTP) has been 
proposed as one of the most probable neuronal substrates underlying plastic changes associated 
with spatial learning and memory1-4. Accordingly, antagonists of NMDARs blocked the induction 
of LTP in hippocampal slices5-7 and impaired reference memory in rats8, 9. Similarly, synaptic 
memory and cognition were influenced by genetically manipulated NMDARs. Indeed, 
hippocampus-related synaptic plasticity and learning were improved in mice over-expressing NR2B 
subunit of these receptors10. Intriguingly, up-regulation of this subunit has been also described 
beneficial for improving cognitive functions in aged mice11. On the other hand, extensive evidence 
suggests that the hippocampus is the main brain region sensitive and vulnerable to age-related loss 
of functional synapses and NMDAR-mediated responses12. Age-related deficits in reference 
memory have been explored across a wide variety of species, especially in rodents, where a decline 
in the hippocampal ability to produce plastic synaptic changes has been documented during aging13-
15. In this respect, alterations of synaptic connectivity and plasticity are thought to be important 
neurobiological determinants in causing the memory deterioration observed in old animals12, 16. 
According to this view, aged rats exhibit reduced NMDAR binding sites, which correlate with their 
impairments in synaptic plasticity and cognition17. 
Although in the past free D-amino acids were considered to be involved only in the “bacterial 
world”, recently, mounting evidence pointed out their neuromodulatory role in controlling neuronal 
functions in mammals. Specifically, the D-amino acid D-serine, by acting as an endogenous co-
agonist at glicyne-binding-sites of NMDARs, has been shown to be able to rescue age-related 
impairment of NMDAR-mediated synaptic potentials in old mice and rats18, 19. Besides D-serine, 
today well characterized for its pharmacological properties and clinical implications in 
schizophrenia treatment20, another D-amino acid, namely D-aspartate, occurs in the mammalian 
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brain. In contrast to the former, the central role of the latter remains, so far, an issue of controversy. 
However, neuro-anatomical and biochemical analyses indicated that in both humans and rodents, D-
aspartate occurs at abundant levels in developing brain to decrease at low amounts during postnatal 
life21, 22. This time-dependent regulation of D-aspartate brain content has been linked to the 
concomitant postnatal expression of D-Aspartate Oxidase (DDO), the only enzyme known so far to 
be responsible for its degradation23, 24. Moreover, in vitro studies pointed out that this D-amino acid 
binds NMDARs25. However, its in vivo relevance in modulating glutamatergic neurotransmission 
remains unclear, since the affinity of these receptors for D-aspartate is 10 times lower than for 
glutamate. Based on these findings, in the present work, we challenged the hypothesis by which 
“forcing” higher D-aspartate levels in aged animals, this in-embryo-occurring molecule might 
disclose neuronal plasticity features aimed to reduce the physiological synaptic and cognitive 
deterioration appearing during brain aging. 
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RESULTS 
D-aspartate triggered NMDAR-dependent and NMDAR-independent currents.  
The pharmacological features of D-aspartate were studied on CA1 pyramidal neurons. NMDA 
induced a remarkable inward current (INMDA), which remained constant after repeated applications 
of the agonist. Perfusion with NVP, a selective NR2A blocker, and cis-PPDA, a NR2C-D 
antagonist, reversibly reduced INMDA to great extent (Fig. 1a,b). In the same neurons, INMDA was 
largely blocked, in an irreversible manner, by Ro 25-6981, a selective NR2B antagonist (Fig. 1 
a,b). Similarly, also D-aspartate-mediated inward currents (ID-Asp) were reduced by each NR2 
selective antagonist (Fig. 1 a,b). Interestingly, while INMDA was totally blocked by the simultaneous 
combination of all NR2 selective antagonists or by the non-competitive NMDAR antagonist, 
MK801 (Fig. 1b), under the same conditions D-aspartate was still able to excite CA1 pyramidal 
neurons (Fig. 1b). Next, we studied the calcium dynamics mediated by D-aspartate, performing 
voltage-clamp recordings associated with microfluorometry with the use of a pipette solution filled 
with the calcium-sensitive dye fura-2. As expected, puff applications of D-aspartate caused an 
inward current that was associated with a transient increase of [Ca2+]i (Fig. 1c). This current was 
largely, but not totally, antagonized in a reversible manner by a high concentration of D-AP5 or 
irreversibly by MK801 (Fig. 1c). Finally, a further set of experiments conducted in the continuous 
presence of MK801 showed that the residual ID-Asp remained constant even with the co-application 
of the sodium-dependent glutamate/aspartate transporter inhibitor DL-TBOA (Fig. 1d). This current 
is rather inhibited by switching the normal ACSF solution to one not containing calcium ions (Fig. 
1d). Notably, chelation of intracellular Ca2+ with EGTA, blockade of all glutamate receptors with 
CNQX and MCPG, and the use of non-specific Voltage Gated Calcium Channel (VGCC) blocker 
cadmium chloride, all added to the superfusion medium, did not affect the remaining Excitatory 
Post Synaptic Currents (EPSC) (Fig. 1d). Therefore, our data indicate that the action of D-aspartate 
on CA1 pyramidal neurons occurs via Ca2+ currents through, at least, two alternative routes based 
on NMDAR-dependent and NMDAR-independent pathways. 
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Lack of D-Aspartate Oxidase induced a dramatic acceleration of age-dependent decay of 
hippocampal synaptic transmission and plasticity. 
We have recently demonstrated that higher D-aspartate levels, in the hippocampus of two-month 
old Ddo-/- mice, enhance the NMDAR-dependent form of LTP, while maintain synaptic 
transmission unaltered26. Based on this study, here we determined the age-related effect of Ddo 
gene ablation on synaptic transmission and plasticity in area CA1. 
Firstly, we examined D-aspartate levels in the hippocampus of Ddo-/- animals and their control 
littermates at 4, 9 and 13 months of age. According to the pivotal role of DDO in controlling D-
aspartate levels, HPLC analysis indicated a strong and persistent hippocampal up-regulation of this 
D-amino acid content throughout all ages tested (Fig. 2a). 
Next, we measured basal synaptic transmission on hippocampal slices from mutants and controls, at 
the same ages at which we evaluated D-aspartate concentrations. At 4 months of age, Ddo+/+ and 
Ddo-/- mice showed similar trendlines (Fig. 2b). Also at 9 months of age, both genotypes exhibited 
comparable fEPSP slopes and fiber volley amplitudes at all stimulus intensities tested (Fig. 2b). In 
contrast, thirteen-month old Ddo-/- animals had significantly reduced maximum fEPSPs, relative to 
Ddo+/+ controls (Fig. 2b). Therefore, these results show that the age-dependent decline in fast 
glutamatergic transmission is exacerbated in absence of DDO enzyme. We then investigated paired-
pulse facilitation (PPF), a measure of short-term plasticity. Interestingly, no differences in the 
paired-pulse ratio between Ddo-/- and Ddo+/+ mice were observed in the three age-group tested (Fig. 
2c). Finally, we explored the effects of deregulated levels of D-aspartate on age-related LTP at CA1 
synapses. At 4 months of age, we showed a significant increase in the magnitude of LTP in Ddo-/- 
animals, compared to control mice (Fig. 2d). In contrast, LTP was impaired either in nine-month 
(Fig. 2d) and, even more severely, in thirteen-month old mutants, when compared to age-matched 
controls (Fig. 2d). Interestingly, at 13 months of age, a physiological decay of LTP appeared also in 
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Ddo+/+ mice that, in any case, never reached the dramatic impairment observed in mutant CA1 
synapses (Fig. 2e). 
 
Ddo-/- mice displayed spatial memory enhancement or worsening in an age-dependent fashion. 
As putative behavioural correlate of hippocampal NMDAR-dependent synaptic plasticity, we 
investigated ontogenetic changes in learning and memory abilities of Ddo-/- mice, at 4, 9 and 13 
months of age, in a reference memory task of the Morris water maze paradigm. 
During acquisition phase, we found similar escape latencies between four-month old Ddo+/+ and 
Ddo-/- animals (Fig. 3a). In order to evaluate their spatial memory formation, we performed two 
retention tests, after a three-day (short) or five-day (long) training period. Interestingly, in probe 1, 
knockout mice displayed a forward ability in remembering the correct location of the platform, 
compared to controls (Fig. 3b). However, after a longer training exposure, both genotypes showed a 
comparable bias spatial search in the target quadrant (Fig. 3c). Then, in order to analyze the ability 
of the mice to erase previous spatial information and planning a new navigation strategy, we moved 
the platform to the opposite position. Also in the reversal phase, both groups displayed similar 
learning abilities (Fig. 3a). Moreover, the results in the retention tests confirmed in Ddo-/- mice an 
improved spatial memory after a short training exposure, compared to controls (Fig. 3d). In fact, 
although both groups showed a search preference for the new goal quadrant, Ddo-/- mice 
significantly spent more time in this location, compared to controls. After additional training, both 
genotypes showed comparable preferential search for the target quadrant (Fig. 3e). 
Also at 9 months of age, both genotypes evidenced comparable spatial learning aptitudes in both 
acquisition and reversal phases (Fig. 3f). Importantly, in probe 1, Ddo-/- group did not confirm 
improved spatial memory, evidenced at 4 months of age (Fig. 3g), since the correct position of the 
platform was acquired only after a longer training (Fig. 3h). Moreover, in the reversal phase, spatial 
retention in the new goal quadrant occurred only in Ddo+/+ animals after five-day training exposure 
(Fig. 3i,j), thus highlighting in mutants the occurrence of mild memory deterioration at this age. 
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The worsening of cognitive aptitudes of Ddo-/- animals was further evidenced in thirteen-month old 
mice. While comparable spatial learning curves were observed for both genotypes during 
acquisition (Fig. 3k), only Ddo+/+ animals showed preserved spatial memory abilities (Fig. 3l,m). In 
the reversal phase, a prominent overall impairment in spatial learning and memory was observed in 
mutants (Fig. 3k,n,o). 
 
Alteration of hippocampal synaptic markers in Ddo-/- mice. 
Here, we analysed whether synaptic and cognitive decline were mirrored by morphological 
variations in the hippocampus of Ddo-/- mice. First, toluidine staining showed no distinguishing 
abnormalities in the pyramidal cell layer and dentate gyrus (DG) of the hippocampus from Ddo+/+ 
and Ddo-/- mice, at any age. This was confirmed by the counting of Neu-N-IR profiles (data not 
shown). A diffuse age-dependent increase in GFAP-IR (Fig. 4h,i,m,n,s) and astrocyte hypertrophy 
(Fig. 4g,l), were observed in the CA3 subfield of the hippocampus, regardless genotype. 
Nevertheless, in the same area, these changes were selectively associated with a reduced 
immunostaining for the presynaptic marker synaptophysin in thirteen-month old Ddo-/- mice (Fig. 
4s) and, interestingly, were anticipated by a decreased staining for the postsynaptic marker MAP2 
in four-month old mutants (Fig. 4s). Synaptophysin significantly decreased also in knockout mice 
in CA1/2 area, at both 4 and 13 months of age (Fig. 4o-s), and in DG of aged mice, compared to 
respective controls (Fig. 4s). Similarly, a reduced pattern of staining for MAP2 was detected in 
CA1/2 field of elderly Ddo-/- mice, compared to age-matched Ddo+/+ animals (Fig. 4a,b,d,e,s). 
Remaining dendrites resulted irregular in shape and size (Fig. 4c,f). Overall, morphological 
alterations found in the hippocampus of old mutants are consistent with the behavioural and 
electrophysiological decline observed during aging. 
 
D-aspartate induced a transient and reversible modulatory effect on NMDAR-dependent 
LTP. 
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To study the in vitro and in vivo consequences associated to non-physiological increased levels of 
D-aspartate, without interfering with Ddo gene expression, we recently developed a 
pharmacological mouse model based on one-month oral administration of this D-amino acid26. 
Taking advantage of this model, we further examined the neurochemical and electrophysiological 
consequences of a more prolonged chronic administration. According to our previous report, we 
found that D-aspartate oral treatment overall resulted in a significant increase of its hippocampal 
content. However, despite the different time-exposure extent, we failed to detect gross differences 
in D-aspartate amount following moderate (3 months) and long-term (12 months) delivery periods  
(Fig. 5a). 
After a three-month administration, C57BL/6J treated mice showed a higher I-O trend, although not 
significant, compared to their untreated controls (Fig. 5b). Similarly, chronic one-year 
administration of D-aspartate produced only a slight decrease in basal transmission. Indeed, 
differently to what observed in mutants, this effect did not reach statistical significance (Fig. 5b), 
demonstrating that even prolonged oral administration of this molecule does not perturb basal 
synaptic responses. Also PPF was indistinguishable in all groups (Fig. 5c). Finally, we examined 
the effects of higher D-aspartate levels on synaptic plasticity in area CA1. Notably, we showed that 
three-month D-aspartate treatment induced a robust enhancement in LTP magnitude (Fig. 5d). 
Interestingly, this plastic augmentation appeared to be regulated through an inducible mechanism, 
since three-week withdrawal was able to reverse this potentiating effect that was, conversely, re-
instated following one-month D-aspartate re-administration (Fig. 5d). In contrast, hippocampal 
slices from twelve-month chronically treated mice were dramatically unresponsive to the 
conditioning train, compared to age-matched controls (Fig. 5e). Moreover, despite what was found 
in Ddo+/+ mice, no signs of age-dependent LTP decay was detected in thirteen-month old untreated 
C57BL/6J mice (Fig. 5f). These results mirrored, to a large extent, those obtained in Ddo-/- mice, 
thus highlighting a common opposing time-dependent effect of chronic D-aspartate exposure on 
hippocampal LTP. To summarize, our data clearly point out that D-aspartate is able to modulate 
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NMDAR-dependent LTP at CA1 synapses and, in turn, provide strong evidence about its role in 
influencing age-dependent changes in synaptic plasticity. 
 
Chronic D-aspartate oral administration in C57BL/6J mice improved spatial memory in 
adulthood without perturbing cognitive functions in elderly phases. 
Spatial learning and memory abilities in D-aspartate treated C57BL/6J mice were analyzed after its 
three-month or twelve-month chronic oral administration, according to the same behavioural 
protocol adopted for mutant animals. During acquisition and reversal phases, three-month D-
aspartate treatment did not produce any visible change in learning aptitudes of mice (Fig. 6a). 
Importantly, after a short training, treated mice evidenced an improvement of spatial memory, as 
indicated by longer search in the goal area, compared to controls (Fig. 6b). Nevertheless, such 
slight difference between groups disappeared after a two-day additional training (Fig. 6c). 
Similarly, during reversal phase, treated animals showed enhanced spatial memory skills, as 
indicated by the longer time spent in the new goal quadrant in the probe 3, compared to non-treated 
mice (Fig. 6d), while both groups were similarly able to remember the position of the new target 
quadrant after five-day training (Fig. 6e). 
Like the shorter treatment, also one-year D-aspartate administration did not modify spatial learning 
performances of C57BL/6J mice (Fig. 6f). Nevertheless, this long-term treatment induced a lack of 
the previous memory enhancement seen in three-month D-aspartate-treated mice. Indeed, no 
differences were detected between D-aspartate-treated and untreated groups in each of the retention 
tests performed (Fig. 6g-j). 
 
D-aspartate rescued CA1 synaptic plasticity decline associated with aging.  
We have previously shown that one-month oral administration of D-aspartate was able to strongly 
increase LTP magnitude in young animals26. Here, we investigated whether such short-term 
treatment might also be beneficial to counterbalance the age-related decay of hippocampus-
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dependent functions. Since it is known that rodent females exhibit a faster rate of deterioration in 
reference memory27, 28, we decided to utilize for this study twelve-month old C57BL/6J females. 
Such females, treated for 1 month with D-aspartate, exhibited a significant increase of this D-amino 
acid levels in their hippocampi, compared to untreated mice (Fig. 7a). Electrophysiological 
experiments indicated no main differences in basal synaptic transmission and short-term plasticity, 
as measured by I–O curves (Fig. 7b) and PPF (data not shown), respectively. In contrast, we found 
a strong enhancement of LTP in treated mice, compared to both age-matched controls (Fig. 7c,d) 
and two-month old C57BL/6J females (Fig. 7c,d). Moreover, according to gender differences 
relative to age-related hippocampal functions, C57BL/6J females showed a pronounced age-
dependent LTP decay, not seen in males (Fig. 7f). 
Finally, we explored spatial cognitive abilities of D-aspartate-treated aged females. Surprisingly, we 
found that treated animals displayed a better spatial learning, compared to untreated mice (Fig. 7e). 
In this regard, it is important to notice that the difference seen after the first training day exclusively 
derives from the second daily session since, in the first test session, mice exhibited comparable 
escape latencies (untreated: 84.25 ± 2.26 s; treated: 76.50 ± 4.21 s). However, according to a more 
relevant age-dependent mnemonic decay likely due to hormonal influences, even after a five-day 
training exposure, both treated and untreated mice did not remember the correct location of the 
platform (Fig. 7f,g). During reversal phase, both groups showed a comparable learning profile (Fig. 
7e). Nevertheless, a mild improvement was detected at days 4 and 5 in D-aspartate treated animals. 
Conversely, no differences were found in the retention tests (Figure 7h,i). 
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DISCUSSION 
While a relevant role for D-aspartate in controlling hormonal activity is well established29, its 
involvement in central functions, so far, remains largely unclear. Indeed, although pharmacological 
studies demonstrated that this D-amino acid binds NMDARs, its in vivo neuromodulatory action is 
still actively debated. In accordance to our previous studies performed on single cells, in CA1 
pyramidal neurons26, here we confirmed the existence of an inward current triggered by D-aspartate, 
not fully suppressed by NMDAR antagonists. For the first time, we demonstrated that D-aspartate-
mediated excitatory currents are exclusively calcium-dependent, since they are abolished by 
perfusion in a calcium-free medium. We were unable, so far, to identify any putative target, since 
the chelation of intracellular calcium and the blockade of all glutamate receptors and VGCC never 
affected this persistent inward current. Therefore, besides demonstrating a direct action on NMDAR 
via interaction with each of NR2A-D subunits, we indicated that the physiological function of D-
aspartate is selectively mediated through a calcium-dependent signalling. Hence, we propose that 
D-aspartate in the brain acts presumably through, at least, two different pathways based on 
NMDAR-dependent and NMDAR-independent signalling. On the other hand, the proposed “dual” 
mechanism of D-aspartate action is also supported by biochemical findings which pointed out a lack 
of functional NMDARs in organs, like testis and adrenal glands, where high levels of this D-amino 
acid were also detected21, 30. 
The pharmacological properties of D-aspartate to act as an endogenous NMDAR agonist are in 
favour of its ability in modulating, among others, synaptic plasticity occurring in the hippocampus 
at CA1 synapses. Accordingly, we have recently demonstrated that non-physiological increase of 
D-aspartate levels in the mouse, achieved either by generating animals with a targeted deletion of 
Ddo gene or by treating mice with D-aspartate for 1 month, enhanced this NMDAR-dependent form 
of LTP26. Based on this, we explored the consequences of deregulated levels of D-aspartate upon 
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hippocampus-related functions during brain aging. Remarkably, we showed that a constitutive 
deregulated high level of D-aspartate in mutant hippocampi (roughly 15-fold, at each age tested) is 
able to act as potent biphasic modulator of neuronal activity: potentiating synaptic memory in adult 
mice (4 months), whilst dramatically accelerating age-dependent basal transmission and LTP decay 
during maturity stages (9-13 months). 
Notably, behavioral studies failed, so far, to reveal consistent learning and memory changes induced 
by D-aspartate in adult animals26, 31. Therefore, in the present study, we carried out a more 
“stringent” spatial cognitive demanding task. In these new setting conditions, a selective 
enhancement of hippocampus-mediated reference memory was found in adult Ddo-/- mice compared 
to their Ddo+/+ littermates. Interestingly, these in vivo data were confirmed in three-month D-
aspartate treated mice. Taken together, such findings are in accordance to those reported in 
ddY/DAO- mutants32 and NR2B transgenic mice10 in which enhanced NMDAR-dependent synaptic 
plasticity mirrored a spatial memory improvement. Moreover, according to Bach et al.33, our studies 
indicated a good correspondence between the biphasic age-dependent LTP changes and spatial 
memory abilities. In fact, while four-month old knockouts displayed enhanced spatial memory, in 
nine- and, even more prominently, thirteen-month old Ddo-/- animals this improvement completely 
disappeared and a significant worsening of cognitive abilities occurred, compared to their relative 
age-matched controls.  
We also showed that, when D-aspartate was administered under an intermittent regimen, this D-
amino acid triggered a transient and reversible enhancement of LTP at CA1 synapses through an 
inducible “turn-on/turn-off-like mechanism”. Hence, these data further corroborated a role for D-
aspartate in regulating NMDAR signalling and, in turn, provided an attractive possibility when 
considering its clinical potential.  
Furthermore, similarly to aged Ddo-/- mice, long-term exposure of D-aspartate evocated a severe 
decay of hippocampal synaptic plasticity. However, differently to the oldest Ddo-/- mice here tested 
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(13 months), one-year D-aspartate chronic administration in C57BL/6J animals failed to produce 
deficits in basal transmission and reference memory. 
Overall, our data strongly supported a neuromodulatory role for D-aspartate on glutamatergic 
transmission and, in turn, showed that, according to its properties as NMDAR agonist, non-
physiological amounts of this molecule in the brain could unmask the opposite neuronal influences 
exerted by this receptor34, 35. In fact, while physiological stimulation of NMDARs has a crucial 
adaptive role in brain processes such as neuronal survival and synaptic plasticity, on the other hand, 
their abnormal activation leads to deregulation of calcium homeostasis, responsible for loss of 
synaptic memory and neurotoxicity34, 36, 37. Consistently, altered LTP has been widely documented in 
hippocampal slices from several transgenic mouse models of Alzheimer Disease (AD)38-41 and in 
senescence-accelerated mouse strains42. In this line, we showed that higher D-aspartate levels render 
glutamatergic synapses more prone to plastic changes, in both four-month old genetic and 
pharmacological animal models, while the prolonged activation of NMDARs in 9-13 month old 
Ddo-/- mice and in long-term treated animals produced a strong accelerated rate of age-dependent 
synaptic plasticity deterioration. 
Nevertheless, our data pointed out also a direct involvement of the specific genetic background on 
which genetic or pharmacological manipulation are studied43,44. In fact, C57BL/6J animals, 
characterized to display very high performances in hippocampus-dependent functions, represent a 
“difficult” mouse strain for easily detecting changes associated to aging45. Thus, even though D-
aspartate induced very strong changes on hippocampal LTP between three- and twelve-month 
treated animals, surprisingly, only mild, if any, differences were found in their spatial memory 
aptitudes. 
On the contrary, based on the observations that C57BL/6J aged females manifested a more 
prominent hippocampal cognitive27 and synaptic memory decline (Fig. 7c,d), compared to males, 
we decided to test whether this embryonic D-amino acid may produce a “youth” influence on 
neuronal plasticity in this more aging-sensitive gender. Remarkably, we showed that one-month 
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oral administration of D-aspartate to one-year old females conferred considerable stronger plastic 
properties, relative to those observed in age-matched controls. The entity of this amelioration was 
even more surprising comparing the level of LTP of these D-aspartate-treated mice to that observed 
in two-month old untreated females. Moreover, this D-amino acid also slightly improved cognitive 
abilities of old females. Taken together, these evidences further extended to aged brains the ability 
of this endogenous D-amino acid to modulate NMDAR-dependent functions. 
In conclusion, our data demonstrated an in vitro and in vivo neuromodulatory role for D-asparate in 
modulating synaptic plasticity and cognition and, in turn, highlighted a crucial, yet unknown, 
implication of DDO in controlling the age-related physiological decline of hippocampus-dependent 
functions. In fact, while the lack of DDO in adult mice induced an enhancement of both LTP and 
spatial memory, at maturity stages it determined a strong acceleration of aging processes, which 
resembled the synaptic and behavioural features described in AD-like animal models38-41. In this line, 
also alterations in synaptic markers MAP2 and synaptophysin found in old mutant hippocampi, are 
consistent to those seen in APP-null mice46. Moreover, the in dissociable opposite age-dependent 
electrophysiological and behavioural phenotypes seen in Ddo-/- mice, let retain these animals as a 
peculiar model for studying in vivo the “Yin and Yang” consequences associated to an abnormal 
NMDARs signalling34. Nevertheless, the lack of gross cognitive alterations after a long-term D-
aspartate chronic administration further supported a potential interest for this D-amino acid when 
considering the beneficial effects of this molecule in attenuating schizophrenia-like symptoms 
induced by amphetamine and MK801 challenges (FE and AU unpublished data). 
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METHODS 
Animals 
Mutant mice for Ddo gene were generated as previously described23. Four-, nine- and thirteen-
month (± 3 weeks) old male wild type (Ddo+/+) and knockout (Ddo-/-) mice were used in this study 
and derived from mating of heterozygous (Ddo+/-) mice, back-crossed to F5 generation to C57BL/6J 
strain47. Animals were genotyped by polymerase chain reaction according to Errico et al.23. 
C57BL/6J male mice were used to test the effects of chronic three- and twelve-month oral 
administration of D-aspartate in neurochemical, cognitive and electrophysiological studies. D-
aspartate was delivered in drinking water at the concentration of 20 mM to 45 days old mice until 
they were used for experiments. Thirteen-month old C57BL/6J female mice were used to test the 
effects of chronic one-month D-aspartate oral administration, delivered between the 12th and the 
13th month of their life.  
Mice were housed in groups (n = 4-5) in standard cages (29 x 17.5 x 12.5 cm) at constant 
temperature (22° ± 1°C) and maintained on a 12/12 h light/dark cycle, with food and water ad 
libitum. Experiments were conducted in conformity with protocols approved by the veterinary 
department of the Italian Ministry of Health and in accordance to the ethical and safety rules and 
guidelines for the use of animals in biomedical research provided by the relevant Italian laws and 
European Union’s directives (n. 86/609/EC). All efforts were made to minimize the animal’s 
suffering. 
 
HPLC analysis 
Mice were killed and the hippocampus dissected and stored at -80°C. The determination of D-
aspartate was performed by HPLC technique, based on the diastereomeric separation of D-aspartate 
from the L-form and other L-amino acids, as previously described48. Data were analysed using 
ANOVA or two-tailed Student’s t test and data are expressed as means ± standard error of the mean 
(SEM). 
 
Morris water maze 
Morris water maze was performed according to a modified version of the protocol described by 
Errico et al.26. The apparatus consisted of a circular pool (100 cm in diameter), surrounded by three-
dimensional visual cues, containing opaque water at 21°C (± 1°C) with a platform (8 cm in 
diameter) submerged 1 cm beneath the water surface. Mice were gently handled 5 min per day for a 
week before the experiment. The acquisition phase consisted of 2 sessions per day (3 h interval 
between sessions) over a five-day period. Each session was composed of 4 trials with an inter-trial 
 17
interval of approximately 5 min. On day 6, the platform was moved to the opposite position and the 
reversal learning was monitored for 5 additional days. Overall, 4 probe tests were performed (2 
tasks per each training phase) in which animals were allowed to swim for 60 s in the absence of the 
platform, in order to evaluate time-dependent memory retention of mice. During acquisition phase, 
the first test (probe 1) was performed before starting the 4th day of training, while the second (probe 
2) was conducted at day 6, before the first session of the reversal phase. During reversal phase, the 
first retention task (probe 3) was done before starting the 9th day of training, while the second 
(probe 4) was conducted at the end of the reversal phase, at day 11. Each retention test was 
conducted about 18 h after the second session of the previous day. In both acquisition and reversal 
phases, the time to reach the target was measured. In the probe tests, the percentage of time spent in 
each quadrant was recorded. A computerized video tracking system (Videotrack, Viewpoint S.A., 
Champagne au Mont d’Or, France) was used for all mentioned parameters. In the acquisition phase, 
the measure of the escape latency was used as dependent variable and data were examined using 
two-way ANOVA (genotype or treatment x days) with repeated measures. Data obtained in the 
probe trials were analysed by one-way ANOVA followed by appropriate post-hoc comparison. A 
significance level of p < 0.05 was accepted as statistically significant in all the experiments 
performed. All measures are expressed as mean ± SEM. All statistical analyses were performed 
with StatView software (version 5.0.1.0; SAS Institute, Cary, NC). 
 
Electrophysiology 
Patch-clamp recordings and microfluorometric measurements.  
Experiments aimed at investigating the effects of D-aspartate application were performed in whole-
cell path-clamp recordings on CA1 pyramidal neurons obtained from juvenile (thirteen- to fifteen-
day-old) Wistar rats. All recordings were obtained in voltage-clamp mode (at –60 mV holding 
potential), in the continuous presence of TTX (1 µM) and nifedipine (10 µM). Vibratome-cut 
parasagittal slices (300 μm) were prepared from hippocampi, incubated for one hour and then 
transferred to a recording chamber submerged in a continuously flowing artificial cerebrospinal 
fluid (30°C, 2-3 ml/min) gassed with 95% O2- 5% CO2. The composition of the control solution 
was (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 11 Glucose, 25 NaHCO3. 
The recording chamber was mounted on the stage of an upright microscope (Axioscope FS, Carl 
Zeiss) equipped for infrared video microscope (Hamamatsu, Japan) and video microfluorometry 
(ImproVision, Coventry, UK). Borosilicate glass electrodes (3-4 MΩ) were filled with (in mM): K-
Gluconate 135; KCl 10; MgCl2 2; CaCl2 0.045; EGTA 0.1; HEPES 10; ATP 2; GTP 0.3 (pH 7.3, 
with KOH). Data were acquired using pClamp and Axoscope software (Axon Instruments). For 
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microfluorometric measurements, neurons were filled with calcium-sensitive dye through the patch 
pipette as described previously49. The fluorescent calcium indicator (fura-2 pentapotassium salt, 
Molecular Probes) was excited via a 40x water immersion objective by illumination with light 
provided by a 75-W Xenon lamp. Excitation light was band-pass-filtered alternatively at 340 or 380 
nm whereas emission light passed a barrier filter (500 nm) and was detected by a CCD camera 
(Photonic Science, Milham, UK). Time courses of fluorescence values, obtained at 340 and 380 nm, 
were calculated over the cell soma (region of interest, ROI) and corrected for background 
fluorescence (BK), measured from a region > 100 μm away from the soma. Changes in 
fluorescence corresponding to calcium concentrations [Ca2+] are reported as ratio values and were 
calculated from the following equation: R=(F340ROI-F340BK) / (F380ROI-F380BK), where F340 
and F380 are the specific fluorescence values emitted by ROI and background at 340 and 380 nm 
excitation wave-lenghts. Drugs were bath-applied by switching the solution to one containing 
known concentrations of drugs. D-aspartate and NMDA were also applied via a patch pipette that 
was positioned in close vicinity of the cell body and was connected to a pressure application system 
(Picospritzer, 20–30 psi, 0.5–1 s).  
Extracellular recordings. 
Ddo-/- mice at different ages and mice chronically treated with D-aspartate (3 and 12 months) were 
compared to their respective controls. Hippocampal slices (400 µm thick) were prepared from 
halothane-anesthetized mice as described above. A bipolar nichrome wire stimulating electrode was 
used to evoke field excitatory postsynaptic potentials (fEPSPs) at approximately 50% of the 
maximal fEPSP amplitude in the Schaffer collateral/commissural fiber pathway. Stimulation pulses 
were delivered at 0.02 Hz for a duration of 0.02 ms. Extracellular recordings of fEPSPs in the 
stratum radiatum of the CA1 region were made using glass microelectrodes filled with ACSF (5–10 
MΩ). I–O, paired-pulse facilitation (PPF) and baseline-normalized LTP fEPSP slope data, were 
grouped according to age and genotype. LTP was induced by a HFS protocol (1 train, 100 Hz, 1 s) 
and the effect of conditioning train was expressed as the mean (±SEM) percentage of baseline EPSP 
slopes measured at 60 min after stimulation protocol. Significance of data were determined using 
the Student’s t test and ANOVA. The p-values were always set at a significance level of less than 
0.05.  
 
Drugs 
D-aspartate, D-(-)-2-amino-5-phosphonoeptanoic acid (AP5), 5S,10R-(+)-5-Methyl-10,11-dihydro-
5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK801), cadmium chloride, L-β-threo-benzyl-
aspartate (DL-TBOA), Tetrodotoxin (TTX), Nifedipine, N-Methyl-D-aspartic acid (NMDA) from 
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Sigma-Aldrich, Milan, Italy; (2S*,3R*)-1-(Phenanthren-2-carbonyl)piperazine-2,3-dicarboxylic 
acid (cis-PPDA), 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX), (aR,bS)-a-(4-Hydroxyphenyl)-b-
methyl-4-(phenylmethyl)-1 -piperidinepropanol maleate (Ro 25-6981) and  MCPG, (RS)-a-Methyl-
4-carboxyphenylglycine (MCPG) from Tocris Cookson Ltd, Bristol, UK. NVP-AAM077 was a 
generous gift from Novartis Pharma AG, Switzerland. 
 
Histology 
All animals were deeply anesthetized with Ketamine (Ketalar, Parke Davis, Italy) 10 mg/kg body 
weight, i.p. (+ diazepam. 2 mg/kg i.m.) and perfused through the ascending aorta with Tyrode-Ca2+ 
free, pH 6.9, followed by 4% paraformaldehyde in Sorensen phosphate buffer 0.1 M pH 7.0. During 
perfusion, animals were bathed in ice-cold water. The brains were then removed and immersed for 
90 min in the same ice-cold fixative, before being rinsed for at least 48 h in 5% sucrose in 0.1M 
phosphate buffer. Brains were frozen in CO2 and 14 μm thick coronal sections were then obtained 
from the dorsal hippocampus at rostro-caudal level –1.58 to –1.94 from the bregma. For 
immunofluorescence experiments, sections were first incubated in 0.1 M phosphate buffered saline 
(PBS) at room temperature for 10-30 min, followed by incubation at 4°C for 24h in a humid 
atmosphere with the primary antibodies diluted in PBS containing 0.3% Triton X-100, v/v (rabbit 
polyclonal anti-MAP-2, Santa Cruz Biotecnology, INC; rabbit polyclonal anti-GFAP, 
EuroDiagnostica; goat polyclonal anti-synaptophysin, Santa Cruz Biotecnology). After rinsing in 
PBS, the sections were incubated at 37°C for 30 min in a humid atmosphere with the secondary 
antisera RedTM X- and CyTM2- conjugated antisera (Jackson Immunoresearch West Grove PA). 
Sections were then rinsed in PBS (as above) and mounted in glycerol containing 1,4-
phenylendiamine 0.1 g/l. 
Images from tissues were taken by Olympus AX70-PROVIS microscope equipped with motorized 
z-stage control and F-VIEW II CCD Camera and processed using Cell^P software (Soft Imaging 
System, GmbH, Munster Germany). Three sections (bilaterally) from each hippocampus were taken 
for analysis of each antigen. The hippocampus was divided into three distinct fields, which were 
labeled as CA1/2, CA3 and DG. Quantification of the tissue staining was performed 
morphometrically by the same investigator who was blinded to the experimental protocol. Shading 
error correction was performed before measurements to correct for irregularities in illumination of 
the microscopic fields. Background levels were equalized and the detection threshold was tested 
and kept at the same level for all samples. MAP2 and GFAP immunostainings were estimated as 
fraction area, whereas synaptophysin staining was examined as optical density. For each animal and 
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histochemical staining, multiple areas were measured and the results were averaged. More details 
on the sampling areas and statistical analysis are included in the legend to the figure. 
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FIGURE LEGENDS 
 
Figure 1. D-aspartate triggers NMDAR-dependent and NMDAR-independent inward currents on 
CA1 pyramidal neurons. (a) Plot of EPSC amplitude vs time showing the effect of pressure applied 
NMDA and D-aspartate on CA1 pyramidal neurons. NMDA-mediated inward current (INMDA 173.6 
± 47.2 pA, p < 0.001, Student’s t test) was reversibly reduced to 66.47 ± 3.18% of control by NVP 
(0.4 µM) (p < 0.001) and to 67.40 ± 3.43% of control by cis-PPDA (10 µM) (p < 0.001). Ro 25-
6981 (5 µM), inhibited INMDA amplitude to 66.99 ± 3.55% of control (p < 0.05) and this effect was 
irreversible at the wash. Similarly, NVP, cis-PPDA and Ro 25-6981 reduced the inward current 
triggered by D-aspartate (ID-Asp 260 ± 84.4 pA) to 66.68 ± 4.88% (p < 0.001), 65.79 ± 5.61% (p < 
0.001) and 67.11 ± 4.62% (p < 0.001) of control, respectively. On top of each plot, traces are 
shown, acquired at the times indicated by the corresponding letters in the plots. Bars indicate the 
time duration of each compound. (b) Summary bar chart representing the pharmacological effects 
of different NMDAR antagonists on the inhibition of current (expressed as mean percentage of 
change ± SEM) triggered by pressure application of NMDA and D-aspartate on at least seven 
separate cells. Notably, INMDA amplitude is totally blocked by the simultaneous application of the 
three selective NR2 antagonists (98.98 ± 0.67% of control, p > 0.1) as well as MK801 (10 µM) 
(99.54 ± 5.18% of control, p > 0.1). In contrast, the ID-Asp amplitude is largely, but not totally, 
inhibited when blocking all NR2 subunits (80.65 ± 0.55% of control, p < 0.05) or by MK801 (82.43 
± 5.92% of control, p < 0.05). (c) Time course of [Ca2+]i in response to a puff-application of D-
aspartate (2 μM) in the presence of D-AP5 (450 μM) and MK801 (10 μM). On top, corresponding 
inward currents elicited by D-aspartate are shown. On the right, images are representative examples 
of a CA1 neuron patch clamped with a pipette containing fura-2 under the three different 
experimental conditions (scale bar, 20 µm). (d) Normalized pooled data (n = 9) of ID-Asp amplitude 
against time, in response to perfusion with MK801 (10 μM), DL-TBOA (100 μM), ACSF calcium 
free, CNQX (30 µM), MCPG (200 µM) and cadmium chloride (100 µM). On top, representative 
raw traces are shown, acquired at the times indicated by the corresponding letters in the plot. Bars 
indicate the time duration of each treatment.   
 
Figure 2. Age-related synaptic deterioration in Ddo-/- mice (a) D-aspartate levels in the 
hippocampus of Ddo+/+ and Ddo-/- mice were measured by HPLC at 4 (Ddo+/+, n = 6; Ddo-/-, n = 3), 
9 (n = 3, per genotype) and 13 (n = 3, per genotype) months of age. At each age analysed, D-
aspartate amount in mutants was significantly higher, compared to their wild type counterpart, 
although no differences were found within groups at different ages. *** = p < 0.0001, compared 
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with control groups (Student’s t test). Values are expressed as mean ± SEM. Genotypes are as 
indicated. (b) Input/output (I/O) curves measured by plotting the fEPSP slopes and their 
corresponding presynaptic fiber volley amplitudes at increasing stimulus strengths are shown for 
Ddo-/- and Ddo+/+ mice at 4, 9 and 13 months of age. At 4 months of age, the trendlines for Ddo+/+ 
and Ddo-/- were: y = 2.30x, R2 =0.96 and y = 2.58x, R2 = 0.88, respectively (p > 0.1). I-O were 
similar also at 9 months of age (y = 1.41x, R2 =0.91 for Ddo+/+, y = 1.37x, R2 = 0.88 for Ddo-/-, p > 
0.1). Conversely, at 13 months of age, basal transmission was impaired in Ddo-/-, relative to Ddo+/+ 
(y = 1.10x, R2 =0.89 for Ddo+/+, y = 0.68x, R2 =0.81 for Ddo-/-, p < 0.05). Each data point is an 
average of two recordings. (c) Paired-pulse facilitation is not altered between the two genotypes in 
the three age groups under observation (p > 0.1, for all comparisons). The facilitation ratio (slope of 
second EPSP/slope of first EPSP) was plotted as a function of interpulse interval, 20, 50, 100, 200 
and 500 ms. For each group, the mean ± SEM is indicated. (d) Superimposed pooled data showing 
the normalized changes in field potential slope (± SEM) in Ddo+/+ and Ddo-/- mice induced by HFS 
protocol. fEPSP slopes were recorded and expressed as the percentage of the pre-tetanus baseline. A 
stimulation intensity that evoked 50% of maximal fEPSP response was used. There was a 
significant increase (p < 0.05) in the magnitude of LTP in four-month old mutants (n = 8), 
compared to control mice (n = 6) (43.9 ± 10.3% above baseline in Ddo+/+, and 61.5 ± 3.3% in Ddo-/-
). At 9 months of age, this tendency was inverted and LTP values were 39.7 ± 9.3% above baseline 
in control (n = 8), and 19.5 ± 2.5% in mutant slices (n = 7). Finally, fEPSP was potentiated to only 
8.5 ± 12.5% in thirteen-month old Ddo-/- mice (n = 6), compared to 30.07 ± 10.4% in age-matched 
Ddo+/+ animals (n = 7). At 9 and 13 months of age, the genotypic effect on LTP was always 
significant (p < 0.001). The arrow represents the HFS used to induce potentiation (e) Summary 
graph (mean ± SEM) showing genotype- and age-effects on the fEPSP slopes (% of baseline) 
quantified 50-60 min after HFS (100 Hz for 1 s). 
 
Figure 3. Memory abilities of Ddo-/- mice improve at adulthood but worsen during aging. (a) Four-
month old Ddo+/+ (n = 14) and Ddo-/- (n = 14) mice were trained for 5 consecutive days in a 
submerged platform version of the Morris water maze (acquisition phase). Two-way ANOVA, with 
escape latency as repeated measure, revealed a significant days effect [F (4, 104) =24.723, p < 
0.0001], non significant genotype effect [F(1, 104) = 0.211, p = 0.6500] and genotype x days 
interaction [F(4, 104) = 0.261, p = 0.9026]. Acquisition phase was followed by a five-day reversal 
phase, in which the submerged platform was moved to the opposite position of the pool (as 
indicated in the figure). Two-way ANOVA showed a significant days effect [F(4, 104)=5.147, p = 
0.0008] but no differences between genotypes [F(1, 104) = 0.717, p = 0.4047] and no interaction 
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between genotype and days [F(4, 104) = 0.898, p = 0.4681]. (b) A 60 s transfer test was performed 
after 3 days of training (probe 1). Ddo-/- animals spent significantly more time in the goal quadrant 
(p < 0.05, compared to right and opposite, p < 0.01 compared to left; Fisher’s post-hoc comparison) 
while Ddo+/+ mice did not show any preference for the target quadrant. (c) A second probe test was 
carried out at the end of acquisition phase (probe 2). After a longer training, targeted spatial 
searching was comparable between wild type and knockout mice (Ddo+/+: p < 0.01, compared to 
others; Ddo-/-: p < 0.05, compared to opposite, p < 0.01, compared to right, p < 0.0001, compared to 
left). (d) After a three-day reversal phase (probe 3), both Ddo+/+ and Ddo-/- animals displayed a 
preference for the new goal quadrant (Ddo+/+: p < 0.05, compared to others; Ddo-/-: p < 0.01, 
compared to old goal and right, p < 0.0001, compared to left) even if knockouts spent significantly 
more time in this area, compared to wild type mice (p < 0.05; Student’s t test). (e) At the end of the 
reversal phase (probe 4), both Ddo+/+ and Ddo-/- mice showed a comparable preference for the new 
goal area (Ddo+/+: p < 0.05, compared to right and left, p < 0.01, compared to old goal; Ddo-/-: p < 
0.05, compared to right, p < 0.01, compared to left and old goal). (f) At 9 months of age, Ddo+/+ (n 
= 10) and Ddo-/- (n = 10) mice showed similar learning abilities both during acquisition [two-way 
ANOVA with repeated measures: days effect, F(4, 72) = 35.729, p < 0.0001; genotype effect, F(1, 72) = 
0.135, p = 0.7179; genotype x days interaction, F(4, 72) = 0.668, p = 0.6160] and reversal phase [two-
way ANOVA with repeated measures: days effect, F(4, 72) = 10.090, p < 0.0001; genotype effect, F(1, 
72) = 0.045, p = 0.8352; genotype x days interaction, F(4, 72) = 0.270, p = 0.8963]. (g) In the first 
retention test, wild type and mutant mice did not show preference for the goal quadrant while, (h) 
after a longer training, both groups spent a significantly longer time in the proper quadrant (Ddo+/+: 
p < 0.01, compared to others; Ddo-/-: p < 0.05, compared to right, p < 0.01, compared to left and 
opposite). Similarly, (i) in the first retention test of the reversal phase, Ddo+/+ and Ddo-/- mice did 
not properly discriminate among quadrants. On the other hand, (j) after a five-day reversal training, 
only Ddo+/+ animals remembered the new targeted location of the platform (p < 0.01, compared to 
right, p < 0.0001, compared to left and old goal). (k) At 13 months of age, both Ddo+/+ (n = 11) and 
Ddo-/- (n = 9) mice showed similar acquisition. Two-way ANOVA revealed a significant days effect 
[F(4, 72) = 8.534, p < 0.0001], non significant genotype effect [F(1, 72) = 4.641E-4, p = 0.9830] and 
genotype x days interaction [F(4, 72) = 1.353, p = 0.2588]. During reversal phase, differently to 
controls, Ddo-/- animals show altered spatial learning [two-way ANOVA: genotype x days 
interaction, F (4, 72) = 3.129, p = 0.0198]. (l) In the transfer test, performed after 3 days of training, 
both Ddo+/+ and Ddo-/- animals showed an unbiased spatial search. (m) In the probe 2, only Ddo+/+ 
mice acquired the information about the correct spatial location of the platform (p < 0.05, compared 
to left, p < 0.01, compared to right and opposite). (n) After a three-day reversal training, mice from 
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both genotypes did not show searching preference for the new goal area. (o) Conversely, in the 
probe 4, wild type, but not knockout mice, remembered the new spatial location of the platform (p < 
0.05, compared to right, p < 0.01, compared to left and old goal). Escape time, expressed in 
seconds, was used as dependent variable in the acquisition and reversal phases. Search quadrant, 
expressed as percentage of time, was used as dependent variable in the probe tests. The dashed lines 
in panels b-e, g-j and l-o indicate the chance level (25%) of search in the four quadrants. * = p < 
0.05 in b, d, j and m;  ** = p < 0.01 in o, between genotypes (Student’s t test). All values are 
expressed as mean ± SEM. Genotypes are as indicated. 
 
Figure 4. Hippocampal synaptic markers are reduced in Ddo-/- mice. Representative, confocal 
images of MAP2 (a-f, o-r, green), NeuN (a, d, red), GFAP (g-n) and synaptophysin- (o-r, red) 
immunostaining in the CA1/2 (a-f, o-r) and CA3 (g-n) hippocampal subfield in four- and thirteen-
month old Ddo+/+ and Ddo-/- mice. In old Ddo-/- mice, a severe reduction of the MAP2-positive 
dendritic tree of pyramidal neurons is observed, compared to wild type (Ddo+/+: a, low power; b, 
high power; Ddo-/-: d, low power; e, high power). Remaining dendrites are irregular in shape and 
size (c: Ddo+/+; f: Ddo-/-). No significant variations in cell density (NeuN-positive nuclei) were 
observed in the pyramidal layer of CA1/2, between genotypes (a: Ddo+/+; d: Ddo-/-). In both 
genotypes, GFAP-IR increases in old (m: Ddo+/+, n: Ddo-/-) compared to young mice (h: Ddo+/+, i: 
Ddo-/-), and high power confocal images of astrocytes indicate hypertrophy of these cells in old 
animals, regardless genotypes (g: young, l: old; Ddo+/+). Synaptophysin, associated to synaptic 
vesicles, depicts apical dendrites and soma of pyramidal neurons in CA1/2 hippocampal field of old 
mice (o, p: Ddo+/+; q, r: Ddo-/-). 
(s) The semiquantitative evaluation of the different immunostainings is shown in the column 
graphs, where black bars refer to Ddo+/+ and white bars to Ddo-/- mice. The percentage area for 
MAP2 and GFAP, and the optical density synaptophysin for young (4 months) and old (13 months) 
mice are illustrated. Data are expressed as mean ± SEM of 4 animals/group. The value in each 
animal derives from 6 measures on adjacent sections. The sampled areas were 15,000 μm2 for 
MAP2 and GFAP; 60,000 μm2 for synaptophysin. One-way ANOVA and Tukey post-hoc test were 
used for statistical analyses. Genotype differences are indicated by asterisks  (* p < 0.05, ** p < 
0.01, *** p < 0.0001) and age differences are indicated by hashes (# p < 0.05; ## p < 0.01). 
Abbreviations: o: stratum oriens; p: stratum pyramidale; r: stratum radiatum; lm: stratum 
lacunosum-moleculare; m: stratum molecular. Bars: a, d, 100 μm; b, e, 50 μm; c, f, 10 μm; h, i, m, 
n, 100 μm; g, l, 10 μm; o, q, 20 μm; p, r, 10 μm. 
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Figure 5. Oral administration of D-aspartate modulates hippocampal synaptic functions at CA1 
synapses. (a) D-aspartate levels were measured by HPLC in the hippocampus of C57BL/6J mice 
treated for 3 (H2O, n = 7; D-aspartate, n = 6) or 12 months (H2O, n = 3; D-aspartate, n = 3) with a 
20 mM D-aspartate solution. Shorter and longer chronic treatments started on 45 days old mice. 
Both treatments significantly increased the hippocampal levels of the D-amino acid, compared to 
respective controls. However, no differences appeared within groups at different ages. * = p < 0.05, 
** = p < 0.01, compared with control groups (Student’s t test). Values are expressed as mean ± 
SEM. Treatments are as indicated. (b) Pooled data (mean ± SEM) showing the relationship between 
fEPSP slope and their corresponding presynaptic fiber volley amplitudes in C57BL/6J D-aspartate 
treated vs untreated mice. Treated mice continuously drank 20 mM D-aspartate for 3 (left panel) or 
12 months (right panel). A regression fit of fEPSP versus presynaptic fiber volley at a stimulating 
intensity that produces 35% of the maximum response shows a similar pattern of response between 
the two groups. The trendlines for I-O curves in three-month treated mice were: y = 2.13x, R2 =0.96 
for treated vs y = 2.70x, R2 =0.91 for untreated animals (p > 0.1). The following trendlines were 
observed following one year chronic treatment: y = 1.56, R2 =0.89 in treated vs y = 2.15x, R2 = 0.96 
in untreated animals (p > 0.1). (c) Pooled data showing the paired-pulse ratio ± S.E.M., against the 
paired-pulse interval following three- and twelve-month D-aspartate treatments vs respective H2O 
groups. No significant differences in paired-pulse facilitation were observed between the two 
treatments, at every tested interval (p > 0.1 for all comparisons). (d) Superimposed pooled data 
showing the normalized changes in field potential slope (± SEM) induced by HFS in three-month 
treated mice vs H2O (left panel). Sixty min after application of HFS, the magnitude of LTP was 52.9 
± 10.1% above baseline in untreated (n = 8) but 74.5 ± 11.5% in three-month treated mice (n = 6) (p 
< 0.001). This potentiating effect was transient (middle panel) since LTP returned to control levels 
(45.1 ± 8.1% above baseline, n = 6, p > 0.05) following a three-week D-aspartate withdrawal, and 
was re-inducible (right panel) after one-month re-administration (62.2 ± 5.9% above baseline, n = 5, 
p < 0.001). (e) Superimposed pooled data showing the effects of continuous one-year D-aspartate 
administration on NMDAR-dependent LTP. The degree of potentiation was 47.15 ± 11.9% above 
baseline in untreated (n = 7) compared to 29.09 ± 2.8% in treated mice (n = 8) (p < 0.001). (f) 
Summary graph (mean ± SEM) showing the modulatory effects of three- vs twelve-month treatment 
on the fEPSP slopes (% of baseline) quantified 50-60 min after HFS. 
 
Figure 6. Chronic D-aspartate treatment enhances spatial memory in C57BL/6J adult mice. (a) 
C57BL/6J mice treated for 3 months with D-aspartate (n = 10) and age-matched untreated animals 
(n = 10) were trained for 5 consecutive days in a submerged platform version of the Morris water 
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maze (acquisition phase). As shown in the figure, platform was subsequently moved to the opposite 
location and mice further trained for 5 days (reversal phase). As indicated by two-way ANOVA 
with repeated measures, treated and untreated mice displayed similar learning profiles, both during 
acquisition [days effect, F(4, 72) = 29.186, p < 0.0001; treatment effect, F(1, 72) = 0.153, p = 0.7001; 
genotype x days interaction, F(4, 72) = 0.545, p = 0.7034] and reversal phase [days effect, F(4, 72) = 
39.970, p < 0.0001; treatment effect, F(1, 72) = 0.534, p = 0.4744; genotype x days interaction, F(4, 72) 
= 1.408, p = 0.2398]. (b) In the first probe test performed after 3 days of training, both groups 
preferentially searched the platform in the proper quadrant (untreated: p < 0.05, compared to others; 
treated: p < 0.01, compared to opposite, p < 0.0001, compared to right and left; Fisher’s post-hoc 
comparison) but treated mice spent significantly more time in this location (p < 0.05, between 
genotypes; Student’s t test). (c) After a five-day training, both D-aspartate treated and untreated 
animals similarly remembered the correct position of the platform (untreated: p < 0.05, compared to 
others; treated: p < 0.05, compared to left, p < 0.01, compared to right, p < 0.0001, compared to 
opposite). (d) Differently to untreated mice, after 3 days of reversal training, D-aspartate treated 
mice were already able to discriminate the new goal quadrant from others (p < 0.05, compared to 
left and old goal, p < 0.01, compared to right) while, (e) after 5 days, both groups displayed a 
similar spatial search (untreated: p < 0.05, compared to others; treated: p < 0.05, compared to left 
and old goal, p < 0.01, compared to right).  (f) After twelve-month D-aspartate treatment, both 
C57BL/6J treated (n = 11) and untreated (n = 10) mice similarly learned the correct location of the 
platform, both during acquisition [days effect, F(4, 76) = 63.430, p < 0.0001; treatment effect, F(1, 76) = 
1.264, p = 0.2748; genotype x days interaction, F(4, 76) = 0.630, p = 0.6424] and reversal phase [days 
effect, F(4, 76) = 16.685, p < 0.0001; treatment effect, F(1, 76) = 0.031, p = 0.8618; genotype x days 
interaction, F(4, 76) = 0.391, p = 0.8144]. (g) In the first probe test, both treated and untreated mice 
were not able to remember the position of the platform. (h) However, after two additional days, 
both D-aspartate- and H2O-treated animals spent significantly more time in the goal quadrant 
(untreated: p < 0.05, compared to left, p < 0.01, compared to right and opposite; treated: p < 0.01, 
compared to others). Similarly, (i) in the first probe test of the reversal phase, both groups displayed 
a random search of the platform while, (j) in the second reference memory task, treated and 
untreated animals showed a bias spatial search in the correct new goal quadrant (untreated: p < 
0.05, compared to right, p < 0.01, compared to left and old goal; treated: p < 0.05, compared to right 
and left, p < 0.01, compared to old goal). Escape time, expressed in seconds, was used as dependent 
variable in the acquisition and reversal phases. Search quadrant, expressed as percentage of time, 
was used as dependent variable in the probe tests. The dashed lines in panels b-e and g-j indicate 
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the chance level (25%) of search in the four quadrants. * = p < 0.05 in b and d, between treatments 
(Student’s t test). All values are expressed as mean ± SEM. Treatments are as indicated. 
 
Figure 7. Beneficial effects of D-aspartate in hippocampus-related functions during aging. All 
experiments were carried out on female C57BL/6J mice. (a) D-aspartate levels were measured by 
HPLC in the hippocampus of thirteen-month old C57BL/6J mice which drank H2O (n = 4) or a 20 
mM D-aspartate solution (n = 3) between their 12th and 13th month of life. One-month D-aspartate 
administration consistently increased the hippocampal levels of this D-amino acid, compared to the 
control. ** = p < 0.01, compared to untreated mice (Student’s t test). Values are expressed as mean 
± SEM. Treatments are as indicated. (b) Superimposed pooled data showing input-output curves in 
two-month (n = 7), thirteen-month old (n = 6) untreated mice and in thirteen-month old D-aspartate 
treated mice (n = 8). No differences were observed among the three groups under observation. (c) 
Superimposed pooled data showing the normalized changes in field potential slope (± SEM) 
induced by HFS in two-month old (58.07 ± 3.1% above baseline, n = 8) vs thirteen-month old 
untreated mice (32.22 ± 6.5% above baseline, n = 6). A treatment with D-aspartate between the 12th 
and the 13th month of life was able to reverse the potentiation decay observed in controls to 82.25 ± 
4.6% above baseline (n = 8). (d) Summary graph (mean ± SEM) showing the fEPSP slopes (% of 
baseline) quantified 50-60 min after HFS (100 Hz for 1 s) in the three groups under observation. 
Notably, the degree of potentiation was significantly higher in treated vs age-matched controls (p < 
0.001). Also the age-dependent effect on the decay of LTP in control animals was significant (p < 
0.001). (e) Thirteen-month old untreated (n = 10) and age-matched D-aspartate treated animals (n = 
10) were employed for 5 consecutive days in a submerged platform version of the Morris water 
maze (acquisition phase). Platform was subsequently moved to the opposite location (as shown in 
the figure) and mice further trained for 5 days (reversal phase). As revealed by two-way ANOVA 
with repeated measures, both groups revealed a significant decrease in the latency to reach the 
platform during the acquisition days [F(4, 72) = 31.347, p < 0.0001], even if treated mice displayed 
improved learning abilities, compared to untreated animals [F(1, 72) = 7.774, p = 0.0121]. During 
reversal phase, both untreated and one-month treated old mice evidenced similar learning abilities 
[days effect, F(4, 72) = 13.232, p < 0.0001; treatment effect, F(1, 72) = 0.251, p = 0.6222; genotype x 
days interaction, F(4, 72) = 1.850, p = 0.1287]. Nevertheless, D-aspartate treatment slightly 
ameliorated learning abilities of mice at day 10 (p < 0.05). In the probe tests performed during 
acquisition phase, however, treated and untreated mice did not display to remember the correct 
location of the platform, both after a (f) shorter and a (g) longer training. During reversal phase, (h) 
both groups displayed a random search of the platform after 3 days of training while, (i) after a 
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longer training period, both treated and untreated mice displayed a significant bias search in the 
proper quadrant (treated and untreated: p < 0.05, compared to others). Escape time, expressed in 
seconds, was used as dependent variable in the acquisition and reversal phases. Search quadrant, 
expressed as percentage of time, was used as dependent variable in the probe tests. The dashed lines 
in panels f-i indicate the chance level (25%) of search in the four quadrants. All values are 
expressed as mean ± SEM. Treatments are as indicated. 
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